Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alifax Holding is an Italian private diagnostics and medical technology company focused on automated clinical laboratory instrumentation and in vitro diagnostics. The group operates through Alifax S.r.l., developing and manufacturing systems used in haematology, microbiology, molecular biology, serology, and autoimmunity laboratories. Its core commercial products include TEST1 2.0 for erythrocyte sedimentation rate testing, Molecular Mouse with Sepsis Panel for rapid real-time PCR pathogen and resistance-gene detection, I-dOne for ATR-FTIR-based microbial identification, and MDRO solutions for antimicrobial resistance screening. The company designs and industrializes its instruments in-house in Italy and sells internationally through subsidiaries and distributors. Alifax is best characterized as a commercial-stage diagnostics company rather than a therapeutics developer, with revenues driven by instrument placements, consumables, and laboratory workflow solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alifax Holding.